Has Jay Youngerman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,072 in general payments to Jay Youngerman, MD across 60 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jay Youngerman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jay Youngerman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jay Youngerman, MD

Otolaryngology · Plainview, NYNPI 1790755072

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,610 of the $3,072 with a category attached, or 85.0%. 17 manufacturers reported payments, led by Aerin Medical Inc. at 47.5% of the total. Reporting peaked in 2023 at $1,099 and has fallen 56.5% since, to $478 in 2025.

$3,072in general payments, 2019–2025

Across 60 payments — averaging $51.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Aerin Medical Inc.$1K
Optinose US, Inc.$364
Stryker$220
Regeneron Healthcare Solutions, Inc.$219
Neurent Medical Limited$172
Inspire Medical Systems, Inc.$150
plus $489 from 11 others

$22,250in research payments, 2019–2025

Across 4 payments — averaging $5562.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AstraZeneca$22K

What the payments were for

Consulting fees$40613%
Food & beverage$2,61085%
Education$562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Aerin Medical Inc.	15	$1,458
Optinose US, Inc.	13	$364
Stryker	6	$220
Regeneron Healthcare Solutions, Inc.	5	$219
Neurent Medical Limited	1	$172
Inspire Medical Systems, Inc.	3	$150
Intersect ENT, Inc.	1	$149
Sanofi	2	$75
Medtronic	1	$44
Arbor Pharmaceuticals, Inc.	2	$42
Novartis	3	$37
Jazz Pharmaceuticals Inc.	2	$35
Mylan Pharmaceuticals Inc.	2	$33
Acclarent, Inc	1	$28
Cook Medical LLC	1	$20
Glenmark Therapeutics Inc.	1	$13
Circassia Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VIVAER STYLUS$1,016
RHINAER STYLUS$1,016
NEUROMARK Device$172
NEUROMARK Radiofrequency Console$172
PROPEL$149
Vivaer RF Stylus$136
ENTELLUS - XPRESS ENT DILATION SYSTEM$125
SPIROX - LATERA$125
Inspire$121
Xhance$118

How this compares

$3,072 in reported general payments places this provider in the 70th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York →

Medicare billing

Part B allowed, 2024

$517,189

Medicare patients

1,121

Services billed

3,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	11	$40,855
Ipratropium Bromide	233	$6,495
Azelastine-FluticasoneAzelastine/Fluticasone	32	$5,273
Dexlansoprazole DrDexlansoprazole	15	$4,475
Azelastine Hcl	152	$3,986
Fluticasone Propionate	164	$3,256
Fluocinolone Acetonide Oil	57	$2,620
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	21	$2,165
Mometasone Furoate	30	$2,020
Famotidine	208	$1,898
Omeprazole	106	$866
Prednisolone Acetate	14	$706
Mupirocin	84	$595
Ofloxacin	23	$528
Montelukast Sodium	27	$308

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Plainview

Parth ShahPlainview$10K
Robert KellmanSyracuse$2.5M
Roheen RaithathaNew York$830K
Nora PerkinsAlbany$300K
Moshe EphratNew Hyde Park$250K
Gavin SetzenAlbany$243K
Habibullah JamalRye Brook$179K
Albert JenFlushing$171K
Dennis KrausNew York$159K
Nitin BhatiaWhite Plains$120K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →